Zhenpeng Guan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhenpeng Guan has a total of 262 co-authors. Here are the top co-authors by number of shared publications:
- Keshi Zhang
Orthopedics Department, Orthopedics Department, Peking University Shougang Hospital, Beijing, Beijing, China
6 shared publications - Junfeng Wang
Department of Orthopedics, Peking University International Hospital, Beijing, China
5 shared publications Keshi Zhang
Department of Orthopedics, Peking University Shougang Hospital, No.9 Jinyuanzhuang Rd, Shijingshan District, 100144 Beijing, PR China
5 shared publicationsZheng Pei
Peking Univ, Dept Orthoped, Shougang Hosp, Beijing 100144, Peoples R China
5 shared publicationsHui Zhang
Department of Orthopedic, Peking University Shougang Hospital, Beijing 100144, China
4 shared publicationsYichuan Wang
Department of Orthopedics, Peking University Shougang Hospital, No.9 Jinyuanzhuang Rd, Shijingshan District, 100144 Beijing, PR China
4 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (9) , 1101-1110
Metal artifact reduction sequence MRI in hip periprosthetic joint infection management
Aims: There is currently no validated noninvasive method to determine infection control prior to prosthesis reimplantation during the two-stage revision process for hip periprosthetic joint infections (PJI) after total hip arthroplasty (THA). This prospective study investigates whether metal artifact reduction sequence (MARS) MRI can serve as a diagnostic reference for infection control before second-stage revision surgery by analyzing artifact-reduced MRIs in patients with hip PJI prior to reimplantation. Methods: Patients with hip PJI after THA who entered the two-stage revision process between January 2019 and January 2024 were prospectively and consecutively enrolled. Based on the Musculoskeletal Infection Society (MSIS) criteria, 23 patients achieved infection control after the interval period (prior to reimplantation), and 11 experienced infection recurrence after spacer implantation (prior to repeat debridement). All patients underwent MARS MRI prior to both first-stage surgery and second-stage reimplantation. Data collected included patient demographics (sex, age), ESR, CRP, intraoperative pathology, culture results, and MARS MRIs. Two imaging specialists reviewed the MARS MRIs obtained prior to the first-stage surgery and prior to the second-stage reimplantation, evaluating regression of prior infectious lesions, emergence of new lesions, and overall infection control. Their assessments were then compared with intraoperative pathology and culture-confirmed infection status. Results: MARS MRI revealed significantly more frequent findings of bone oedema, soft-tissue oedema, and joint effusion in patients with recurrent infection compared to those with controlled infection after spacer implantation (p = 0.002). The imaging specialists’ evaluations were in complete agreement with the clinical findings confirmed by pathology and cultures. Conclusion: Evaluating the difference in MARS MRIs between the first-stage and second-stage preoperative periods, and focusing on oedema signals in the bone and soft tissues surrounding the prosthesis, provides a useful noninvasive indicator for determining infection control prior to two-stage reimplantation. Cite this article: Bone Joint Res 2026;15(9):1101–1110.
- 4 September 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 15 (9) , 1101-1110
Open AccessMetal artifact reduction sequence MRI in hip periprosthetic joint infection management
Aims: There is currently no validated noninvasive method to determine infection control prior to prosthesis reimplantation during the two-stage revision process for hip periprosthetic joint infections (PJI) after total hip arthroplasty (THA). This prospective study investigates whether metal artifact reduction sequence (MARS) MRI can serve as a diagnostic reference for infection control before second-stage revision surgery by analyzing artifact-reduced MRIs in patients with hip PJI prior to reimplantation. Methods: Patients with hip PJI after THA who entered the two-stage revision process between January 2019 and January 2024 were prospectively and consecutively enrolled. Based on the Musculoskeletal Infection Society (MSIS) criteria, 23 patients achieved infection control after the interval period (prior to reimplantation), and 11 experienced infection recurrence after spacer implantation (prior to repeat debridement). All patients underwent MARS MRI prior to both first-stage surgery and second-stage reimplantation. Data collected included patient demographics (sex, age), ESR, CRP, intraoperative pathology, culture results, and MARS MRIs. Two imaging specialists reviewed the MARS MRIs obtained prior to the first-stage surgery and prior to the second-stage reimplantation, evaluating regression of prior infectious lesions, emergence of new lesions, and overall infection control. Their assessments were then compared with intraoperative pathology and culture-confirmed infection status. Results: MARS MRI revealed significantly more frequent findings of bone oedema, soft-tissue oedema, and joint effusion in patients with recurrent infection compared to those with controlled infection after spacer implantation (p = 0.002). The imaging specialists’ evaluations were in complete agreement with the clinical findings confirmed by pathology and cultures. Conclusion: Evaluating the difference in MARS MRIs between the first-stage and second-stage preoperative periods, and focusing on oedema signals in the bone and soft tissues surrounding the prosthesis, provides a useful noninvasive indicator for determining infection control prior to two-stage reimplantation. Cite this article: Bone Joint Res 2026;15(9):1101–1110.
- Open Access
- 20 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (1) , 100737
A randomized, double-blind, placebo-controlled and dose-ranging study to evaluate the safety and efficacy of XG005 in subjects with painful osteoarthritis of the knee
- 20 December 2025
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (1) , 100737
Open AccessA randomized, double-blind, placebo-controlled and dose-ranging study to evaluate the safety and efficacy of XG005 in subjects with painful osteoarthritis of the knee
- Open Access
- 12 November 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (1) , 1-15
Identification of multimorbidity hub genes for knee osteoarthritis-atherosclerosis and potential clinical applications
The combination of knee osteoarthritis (KOA) and atherosclerosis (AS) is a common multimorbidity. Epidemiological studies have demonstrated the existence of common risk factors, with metabolic syndrome possibly considered the most critical. In the present study, metabolism‑related clinical information was analyzed and metabolic profiles were assessed in healthy controls, patients with KOA, patients with AS and patients with both conditions using untargeted serum metabolomics assays. Potential KOA‑AS multimorbidity hub genes were identified using transcriptomics datasets from the Gene Expression Omnibus database and were validated using clinical samples and animal experiments. Finally, the clinical applications of the analyzed biomolecules were predicted. The results showed that the caffeine metabolic pathway was markedly associated with KOA‑AS multimorbidity and caffeine interacted with two potential hub genes (EGR1 and GSK3B). In the validation experiment using clinical samples, early growth response 1 (Egr1) protein was only associated with AS. In the mouse disease model, Egr1 protein in the serum and cartilage was associated with KOA‑AS multimorbidity, with consistent expression trends. Receiver operating characteristic (ROC) analysis showed three metabolites with an area under the ROC curve of >0.7; drug prediction yielded two drugs that interacted with EGR1. In conclusion, KOA‑AS multimorbidity may be associated with metabolic abnormalities in the early stages and could develop into chronic inflammation in the later stages. Through multi‑omics analysis, three caffeine‑related metabolites with diagnostic value were obtained and EGR1 was identified as the key gene for KOA‑AS multimorbidity.
- 12 November 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 33 (1) , 1-15
Open AccessIdentification of multimorbidity hub genes for knee osteoarthritis-atherosclerosis and potential clinical applications
The combination of knee osteoarthritis (KOA) and atherosclerosis (AS) is a common multimorbidity. Epidemiological studies have demonstrated the existence of common risk factors, with metabolic syndrome possibly considered the most critical. In the present study, metabolism‑related clinical information was analyzed and metabolic profiles were assessed in healthy controls, patients with KOA, patients with AS and patients with both conditions using untargeted serum metabolomics assays. Potential KOA‑AS multimorbidity hub genes were identified using transcriptomics datasets from the Gene Expression Omnibus database and were validated using clinical samples and animal experiments. Finally, the clinical applications of the analyzed biomolecules were predicted. The results showed that the caffeine metabolic pathway was markedly associated with KOA‑AS multimorbidity and caffeine interacted with two potential hub genes (EGR1 and GSK3B). In the validation experiment using clinical samples, early growth response 1 (Egr1) protein was only associated with AS. In the mouse disease model, Egr1 protein in the serum and cartilage was associated with KOA‑AS multimorbidity, with consistent expression trends. Receiver operating characteristic (ROC) analysis showed three metabolites with an area under the ROC curve of >0.7; drug prediction yielded two drugs that interacted with EGR1. In conclusion, KOA‑AS multimorbidity may be associated with metabolic abnormalities in the early stages and could develop into chronic inflammation in the later stages. Through multi‑omics analysis, three caffeine‑related metabolites with diagnostic value were obtained and EGR1 was identified as the key gene for KOA‑AS multimorbidity.
- Open Access
- 17 September 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (21) , 2813-2823
Kaempferide inhibited progression of osteoarthritis by targeting the HIF-1 signaling pathway
Background: Osteoarthritis (OA) is a prevalent joint disorder that significantly impairs quality of life among elderly individuals because of chronic pain and physical disability. As the global burden of OA continues to rise, novel therapeutic strategies are urgently needed. Kaempferide (KA), a flavonoid derived from traditional Chinese herbal medicine, is known for its anti-inflammatory properties. However, the effect of KA on the progression of OA has not been well investigated. This study aimed to explore the therapeutic potential of KA in an OA model and investigate the underlying mechanisms via transcriptomic sequencing. Methods: An in vitro OA model was established using SW1353 cells treated with interleukin-1 beta (IL-1β) and different concentrations of KA (30, 60, or 90 μmol/L) for 24 h. The anti-inflammatory effects of KA were assessed using quantitative real-time polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay (ELISA), and Western blotting. In vivo , a papain-induced OA rat model was used to evaluate the therapeutic effects of KA through histological and behavioral analyses. Transcriptomic sequencing was performed to explore the differentially expressed genes (DEGs) and related signaling pathways. Statistical analysis was conducted using one-way analysis of variance. Results: KA significantly increased cell viability in the OA chondrocyte model and downregulated the expression of inflammatory cytokines and cartilage degradation markers, with the greatest reduction observed at 90 μmol/L. In vivo , KA treatment mitigated cartilage degradation and improved gait behavior in OA rats. Transcriptomic analysis revealed substantial modulation of DEGs, implicating the hypoxia-inducible factor-1 (HIF-1) signaling pathway as a key mechanism. Further blocking and rescue experiments revealed that KA regulated key molecules within the HIF-1 pathway, specifically interferon-gamma (IFN-γ) and hypoxia-inducible factor 1-alpha (HIF-1α), confirming their critical roles in mediating the therapeutic effects of KA. Conclusion: KA inhibited the progression of OA by targeting the HIF-1 signaling pathway, reducing inflammation, and cartilage degradation.
- 17 September 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (21) , 2813-2823
Open AccessKaempferide inhibited progression of osteoarthritis by targeting the HIF-1 signaling pathway
Background: Osteoarthritis (OA) is a prevalent joint disorder that significantly impairs quality of life among elderly individuals because of chronic pain and physical disability. As the global burden of OA continues to rise, novel therapeutic strategies are urgently needed. Kaempferide (KA), a flavonoid derived from traditional Chinese herbal medicine, is known for its anti-inflammatory properties. However, the effect of KA on the progression of OA has not been well investigated. This study aimed to explore the therapeutic potential of KA in an OA model and investigate the underlying mechanisms via transcriptomic sequencing. Methods: An in vitro OA model was established using SW1353 cells treated with interleukin-1 beta (IL-1β) and different concentrations of KA (30, 60, or 90 μmol/L) for 24 h. The anti-inflammatory effects of KA were assessed using quantitative real-time polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay (ELISA), and Western blotting. In vivo , a papain-induced OA rat model was used to evaluate the therapeutic effects of KA through histological and behavioral analyses. Transcriptomic sequencing was performed to explore the differentially expressed genes (DEGs) and related signaling pathways. Statistical analysis was conducted using one-way analysis of variance. Results: KA significantly increased cell viability in the OA chondrocyte model and downregulated the expression of inflammatory cytokines and cartilage degradation markers, with the greatest reduction observed at 90 μmol/L. In vivo , KA treatment mitigated cartilage degradation and improved gait behavior in OA rats. Transcriptomic analysis revealed substantial modulation of DEGs, implicating the hypoxia-inducible factor-1 (HIF-1) signaling pathway as a key mechanism. Further blocking and rescue experiments revealed that KA regulated key molecules within the HIF-1 pathway, specifically interferon-gamma (IFN-γ) and hypoxia-inducible factor 1-alpha (HIF-1α), confirming their critical roles in mediating the therapeutic effects of KA. Conclusion: KA inhibited the progression of OA by targeting the HIF-1 signaling pathway, reducing inflammation, and cartilage degradation.
- Open Access
- 25 April 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (6) , 4080-4085
Management of posterior cruciate ligament injuries: an expert consensus from 17 countries
Background: Posterior cruciate ligament (PCL) injury is a relatively common musculoskeletal condition. However, there is currently a lack of consensus on decision-making, treatment and postoperative management for such injuries. Objectives: To use the modified Delphi method to reach expert consensus on the management of PCL injury. Methods: A literature search of PubMed, Cochrane Library, Embase, and Web of Science for articles up to 17 October 2024, to support the development of recommendation statements. An Expert Panel of 90 experienced clinicians from orthopedics and sports medicine participated in a two-round Delphi process. Each statement was evaluated in two parts: the first part assessed content appropriateness (score of 7–9 indicating appropriateness and 4–6 indicating possible appropriateness), while the second part assessed agreement (score of 5–9 indicating agreement). Results: The panel members developed 11 statements using the Delphi process, addressing the following topics: (1) clinical decision-making, (2) treatment, and (3) postoperative management about PCL injuries. The final consensus was reached on 11 statements and we eventually translated these statements into a corresponding table of expert recommendations. Conclusion: Consensus was reached on 11 statements regarding three aspects of PCL injury management. These findings provide a foundation for developing evidence-based guidelines that can enhance clinical decision-making, improve treatment strategies, and optimize postoperative care for patients with PCL injuries.
- 25 April 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (6) , 4080-4085
Open AccessManagement of posterior cruciate ligament injuries: an expert consensus from 17 countries
Background: Posterior cruciate ligament (PCL) injury is a relatively common musculoskeletal condition. However, there is currently a lack of consensus on decision-making, treatment and postoperative management for such injuries. Objectives: To use the modified Delphi method to reach expert consensus on the management of PCL injury. Methods: A literature search of PubMed, Cochrane Library, Embase, and Web of Science for articles up to 17 October 2024, to support the development of recommendation statements. An Expert Panel of 90 experienced clinicians from orthopedics and sports medicine participated in a two-round Delphi process. Each statement was evaluated in two parts: the first part assessed content appropriateness (score of 7–9 indicating appropriateness and 4–6 indicating possible appropriateness), while the second part assessed agreement (score of 5–9 indicating agreement). Results: The panel members developed 11 statements using the Delphi process, addressing the following topics: (1) clinical decision-making, (2) treatment, and (3) postoperative management about PCL injuries. The final consensus was reached on 11 statements and we eventually translated these statements into a corresponding table of expert recommendations. Conclusion: Consensus was reached on 11 statements regarding three aspects of PCL injury management. These findings provide a foundation for developing evidence-based guidelines that can enhance clinical decision-making, improve treatment strategies, and optimize postoperative care for patients with PCL injuries.
- Open Access
- 4 August 2023
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 136 (18) , 2187-2194
Efficacy and safety of flurbiprofen cataplasms versus loxoprofen sodium cataplasms in knee osteoarthritis: a randomized controlled trial
Background: Clinical trial evidence is limited to identify better topical non-steroidal anti-inflammatory drugs (NSAIDs) for treating knee osteoarthritis (OA). We aimed to compare the clinical efficacy and safety of flurbiprofen cataplasms (FPC) with loxoprofen sodium cataplasms (LSC) in treating patients with knee OA. Methods: This is an open-label, non-inferiority randomized controlled trial conducted at Peking University Shougang Hospital. Overall, 250 patients with knee OA admitted from October 2021 to April 2022 were randomly assigned to FPC and LSC treatment groups in a 1:1 ratio. Both medications were administered to patients for 28 days. The primary outcome was the change of pain measured by visual analog scale (VAS) score from baseline to day 28 (range, 0–10 points; higher score indicates worse pain; non-inferiority margin: 1 point; superiority margin: 0 point). There were four secondary outcomes, including the extent of pain relief, the change trends of VAS scores, joint function scores measured by the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and adverse events. Results: Among 250 randomized patients (One patient without complete baseline record in the flurbiprofen cataplasms was excluded; age, 62.8 ± 10.5 years; 61.4% [153/249] women), 234 (93.6%) finally completed the trial. In the intention-to-treat analysis, the decline of the VAS score for the 24-h most intense pain in the FPC group was non-inferior, and also superior to that in the LSC group (differences and 95% confidence interval, 0.414 (0.147–0.681); P P = 0.001 for superiority). Similar results were observed of the VAS scores for the current pain and pain during exercise. WOMAC scores were also lower in the FPC group at week 4 (12.50 [8.00–22.50] vs . 16.00 [11.00–27.00], P = 0.010), mainly driven by the dimension of daily activity difficulty. In addition, the FPC group experienced a significantly lower incidence of adverse events (5.6% [7/124] vs . 33.6% [42/125], P <0.001), including irritation, rash and pain of the skin, and sticky hair uncovering pain. Conclusions: This study suggested that FPC is superior to LSC for treating patients with knee OA in pain relief, joint function improvement, and safety profile.
- 4 August 2023
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 136 (18) , 2187-2194
Open AccessEfficacy and safety of flurbiprofen cataplasms versus loxoprofen sodium cataplasms in knee osteoarthritis: a randomized controlled trial
Background: Clinical trial evidence is limited to identify better topical non-steroidal anti-inflammatory drugs (NSAIDs) for treating knee osteoarthritis (OA). We aimed to compare the clinical efficacy and safety of flurbiprofen cataplasms (FPC) with loxoprofen sodium cataplasms (LSC) in treating patients with knee OA. Methods: This is an open-label, non-inferiority randomized controlled trial conducted at Peking University Shougang Hospital. Overall, 250 patients with knee OA admitted from October 2021 to April 2022 were randomly assigned to FPC and LSC treatment groups in a 1:1 ratio. Both medications were administered to patients for 28 days. The primary outcome was the change of pain measured by visual analog scale (VAS) score from baseline to day 28 (range, 0–10 points; higher score indicates worse pain; non-inferiority margin: 1 point; superiority margin: 0 point). There were four secondary outcomes, including the extent of pain relief, the change trends of VAS scores, joint function scores measured by the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and adverse events. Results: Among 250 randomized patients (One patient without complete baseline record in the flurbiprofen cataplasms was excluded; age, 62.8 ± 10.5 years; 61.4% [153/249] women), 234 (93.6%) finally completed the trial. In the intention-to-treat analysis, the decline of the VAS score for the 24-h most intense pain in the FPC group was non-inferior, and also superior to that in the LSC group (differences and 95% confidence interval, 0.414 (0.147–0.681); P P = 0.001 for superiority). Similar results were observed of the VAS scores for the current pain and pain during exercise. WOMAC scores were also lower in the FPC group at week 4 (12.50 [8.00–22.50] vs . 16.00 [11.00–27.00], P = 0.010), mainly driven by the dimension of daily activity difficulty. In addition, the FPC group experienced a significantly lower incidence of adverse events (5.6% [7/124] vs . 33.6% [42/125], P <0.001), including irritation, rash and pain of the skin, and sticky hair uncovering pain. Conclusions: This study suggested that FPC is superior to LSC for treating patients with knee OA in pain relief, joint function improvement, and safety profile.
- Open Access
- 11 April 2022
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 23 (1) , 1-8
Vaspin promotes chondrogenic differentiation of BMSCs via Akt activation in osteoarthritis
Background: The aim of this study was to investigate the role of Vaspin on the chondrogenic differentiation of bone mesenchymal stem cells (BMSCs), and its effect on chondrocyte survival and ECM secretion. We also assessed whether the Akt activation participates in these processes. Methods: In vivo, immunohistochemistry was used to examine the positive rate of the protein expressions of Akt in Wistar rat articular cartilage and subchondral bone after Vaspin intraperitoneal injection for 14 days. In vitro, we isolated and expanded BMSCs from Wistar rats, and further cultured BMSCs as pellets in a chondrogenic-differentiation medium supplemented with different concentrations of Vaspin. After 21 days, the pellets were processed for cell counting kit assay. The mRNA level of Akt, SOX9 and COL2A1 in the pellets were investigated using quantitative Real-Time polymerase chain reaction, and the protein level of COMP was detected using western blot. Results: During the chondrogenic differentiation of BMSCs, Vaspin promoted the chondrogenic differentiation of BMSCs and chondrocyte survival by activating the Akt pathway. These effects were significantly reduced by treatment with an Akt inhibitor. Moreover, Vaspin promoted chondrogenic differentiation of BMSCs by increasing the expression of markers in cartilage formation and extracellular matrix secretion. Furthermore, our study also found that Vaspin could increase Akt expression in cartilage cavities and subchondral bone in vivo. Conclusion: These findings demonstrate that Vaspin can promote the chondrogenic differentiation of BMSCs and chondrocyte survival via Akt activation. Our study provides new insights into the potential ability of Vaspin to ameliorate the chondrogenic differentiation of BMSCs and chondrocyte survival in OA.
- 11 April 2022
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 23 (1) , 1-8
Open AccessVaspin promotes chondrogenic differentiation of BMSCs via Akt activation in osteoarthritis
Background: The aim of this study was to investigate the role of Vaspin on the chondrogenic differentiation of bone mesenchymal stem cells (BMSCs), and its effect on chondrocyte survival and ECM secretion. We also assessed whether the Akt activation participates in these processes. Methods: In vivo, immunohistochemistry was used to examine the positive rate of the protein expressions of Akt in Wistar rat articular cartilage and subchondral bone after Vaspin intraperitoneal injection for 14 days. In vitro, we isolated and expanded BMSCs from Wistar rats, and further cultured BMSCs as pellets in a chondrogenic-differentiation medium supplemented with different concentrations of Vaspin. After 21 days, the pellets were processed for cell counting kit assay. The mRNA level of Akt, SOX9 and COL2A1 in the pellets were investigated using quantitative Real-Time polymerase chain reaction, and the protein level of COMP was detected using western blot. Results: During the chondrogenic differentiation of BMSCs, Vaspin promoted the chondrogenic differentiation of BMSCs and chondrocyte survival by activating the Akt pathway. These effects were significantly reduced by treatment with an Akt inhibitor. Moreover, Vaspin promoted chondrogenic differentiation of BMSCs by increasing the expression of markers in cartilage formation and extracellular matrix secretion. Furthermore, our study also found that Vaspin could increase Akt expression in cartilage cavities and subchondral bone in vivo. Conclusion: These findings demonstrate that Vaspin can promote the chondrogenic differentiation of BMSCs and chondrocyte survival via Akt activation. Our study provides new insights into the potential ability of Vaspin to ameliorate the chondrogenic differentiation of BMSCs and chondrocyte survival in OA.
- Open Access
- 28 January 2022
- Published by Wiley in Orthopaedic Surgery
- Vol. 14 (3) , 595-604
Corresponding Changes of Autophagy‐Related Genes and Proteins in Different Stages of Knee Osteoarthritis: An Animal Model Study
Objective: To investigate the effect of autophagy expression levels of different weight‐bearing states and different stages of osteoarthritis in animal models, as well as the corresponding mechanisms.Methods: We used the male Sprague–Dawley (SD) rats (12‐week‐old, SPF) to establish the OA animal models by modified Hulth method, and grouped animal models according to the length of time after surgery and different weight‐bearing areas. RT‐qPCR was carried out for detection of autophagy‐related genes such as Atg7, Atg12, P62, etc. Western blot analysis was used to detect the expression levels of corresponding autophagy‐related proteins such as LC3B, P62, etc. T test was performed for statistical analysis to compare different groups, while the differences were deemed statistically significant with P < 0.05. Transmission electron microscopy was used to observe the autophagosome to demonstrate the level of autophagy expression and the status of the chondrocytes.Results: The results of the RT‐qPCR testing showed that when the weight‐bearing cartilage of the 4‐week group (relatively mild) was compared with that of the 10‐week group (relatively severe), there were statistically significant differences in all the genes tested, in detail: Atg3 (P < 0.01), Atg7 (P < 0.01), Atg12 (P < 0.01), P62 (P < 0.0001). The expression of autophagy‐related mRNA in the 4‐week group is increased compared with that of the 10‐week group. As for the expression of proteins, Western blotting showed that in the comparison between the 4‐ and the 10‐week groups, statistically significant results include Atg12 (P < 0.01) in the non‐weight‐bearing area, with decreased autophagy in the 10‐week group compared with that of the 4‐week group, while expression of LC3B (P < 0.05) protein was significantly higher in the 4‐week group than in the control in the non‐weight‐bearing area. The expression of LC3B (P < 0.0001) and P62 (P < 0.05) in the 10‐week group were higher than that of the control. Transmission electron microscope showed that autophagy in the weight‐bearing area is stronger than that in the non‐weight‐bearing area, and autophagy in the 4‐week group is stronger than in the 10‐week group for the weight‐bearing area.Conclusions: The expression of autophagy varies during different stages of osteoarthritis, in which the autophagy is stronger in the early stage of osteoarthritis, and gradually decreases with the progression of the disease. Autophagy in different weight‐bearing areas may also be different.
- 28 January 2022
- Published by Wiley in Orthopaedic Surgery
- Vol. 14 (3) , 595-604
Open AccessCorresponding Changes of Autophagy‐Related Genes and Proteins in Different Stages of Knee Osteoarthritis: An Animal Model Study
Objective: To investigate the effect of autophagy expression levels of different weight‐bearing states and different stages of osteoarthritis in animal models, as well as the corresponding mechanisms.Methods: We used the male Sprague–Dawley (SD) rats (12‐week‐old, SPF) to establish the OA animal models by modified Hulth method, and grouped animal models according to the length of time after surgery and different weight‐bearing areas. RT‐qPCR was carried out for detection of autophagy‐related genes such as Atg7, Atg12, P62, etc. Western blot analysis was used to detect the expression levels of corresponding autophagy‐related proteins such as LC3B, P62, etc. T test was performed for statistical analysis to compare different groups, while the differences were deemed statistically significant with P < 0.05. Transmission electron microscopy was used to observe the autophagosome to demonstrate the level of autophagy expression and the status of the chondrocytes.Results: The results of the RT‐qPCR testing showed that when the weight‐bearing cartilage of the 4‐week group (relatively mild) was compared with that of the 10‐week group (relatively severe), there were statistically significant differences in all the genes tested, in detail: Atg3 (P < 0.01), Atg7 (P < 0.01), Atg12 (P < 0.01), P62 (P < 0.0001). The expression of autophagy‐related mRNA in the 4‐week group is increased compared with that of the 10‐week group. As for the expression of proteins, Western blotting showed that in the comparison between the 4‐ and the 10‐week groups, statistically significant results include Atg12 (P < 0.01) in the non‐weight‐bearing area, with decreased autophagy in the 10‐week group compared with that of the 4‐week group, while expression of LC3B (P < 0.05) protein was significantly higher in the 4‐week group than in the control in the non‐weight‐bearing area. The expression of LC3B (P < 0.0001) and P62 (P < 0.05) in the 10‐week group were higher than that of the control. Transmission electron microscope showed that autophagy in the weight‐bearing area is stronger than that in the non‐weight‐bearing area, and autophagy in the 4‐week group is stronger than in the 10‐week group for the weight‐bearing area.Conclusions: The expression of autophagy varies during different stages of osteoarthritis, in which the autophagy is stronger in the early stage of osteoarthritis, and gradually decreases with the progression of the disease. Autophagy in different weight‐bearing areas may also be different.
- Open Access
- 22 November 2021
- Published by Wiley in Brain and Behavior
- Vol. 11 (12) , e32420
Identification of risk factors for postoperative delirium in elderly patients with hip fractures by a risk stratification index model: A retrospective study
Introduction: Postoperative delirium is one of the most common and dangerous psychiatric complications after hip surgery. The aim of this study was to investigate the incidence of postoperative delirium in elderly patients after hip fracture surgery and to identify risk factors for such, as part of developing a risk stratification index (RSI) system to predict a patient's risk of postoperative delirium.Methods: Elderly patients (aged 65 years or older) with hip fractures who had received surgical treatment in our hospital between March 2018 and December 2019 were retrospectively included. Clinical data were collected, and multivariate logistic regression analysis was performed to investigate the relevant risk factors of postoperative delirium. An RSI system was developed based on factors identified in the regression analysis.Results: Of 272 patients included, 52 (19.12%) experienced postoperative delirium. Drinking history (> 3/ week), the perioperative lactic acid level (Lac > 2 mmol/L), postoperative visual analog score (VAS) > 3, American Society of Anesthesiologists (ASA) physical status > II, application of the bispectral index, and preoperative diabetes were independent risk factors of postoperative delirium. When RSI ≥ 5, the rate of postoperative delirium significantly increased (p < .05).Conclusion: The RSI system developed here can safely guide postoperative outcomes of elderly patients with hip fractures, and RSI ≥ 5 may be able to predict the onset of postoperative delirium.
- 22 November 2021
- Published by Wiley in Brain and Behavior
- Vol. 11 (12) , e32420
Open AccessIdentification of risk factors for postoperative delirium in elderly patients with hip fractures by a risk stratification index model: A retrospective study
Introduction: Postoperative delirium is one of the most common and dangerous psychiatric complications after hip surgery. The aim of this study was to investigate the incidence of postoperative delirium in elderly patients after hip fracture surgery and to identify risk factors for such, as part of developing a risk stratification index (RSI) system to predict a patient's risk of postoperative delirium.Methods: Elderly patients (aged 65 years or older) with hip fractures who had received surgical treatment in our hospital between March 2018 and December 2019 were retrospectively included. Clinical data were collected, and multivariate logistic regression analysis was performed to investigate the relevant risk factors of postoperative delirium. An RSI system was developed based on factors identified in the regression analysis.Results: Of 272 patients included, 52 (19.12%) experienced postoperative delirium. Drinking history (> 3/ week), the perioperative lactic acid level (Lac > 2 mmol/L), postoperative visual analog score (VAS) > 3, American Society of Anesthesiologists (ASA) physical status > II, application of the bispectral index, and preoperative diabetes were independent risk factors of postoperative delirium. When RSI ≥ 5, the rate of postoperative delirium significantly increased (p < .05).Conclusion: The RSI system developed here can safely guide postoperative outcomes of elderly patients with hip fractures, and RSI ≥ 5 may be able to predict the onset of postoperative delirium.
- Top Cited PapersOpen Access
- 1 July 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 174, 504-534
Pharmaceutical electrospinning and 3D printing scaffold design for bone regeneration
- 1 July 2021
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 174, 504-534
Top Cited PapersOpen AccessPharmaceutical electrospinning and 3D printing scaffold design for bone regeneration